Argenta Discovery signs deal with Japanese pharmaceutical company
UK company Argenta Discovery has entered into a collaboration with the Japanese pharmaceutical company Teijin, under which it will exploit a range of approaches to deliver an optimised lead series against a cardiovascular disease target.
UK company Argenta Discovery has entered into a collaboration with the Japanese pharmaceutical company Teijin, under which it will exploit a range of approaches to deliver an optimised lead series against a cardiovascular disease target.
Aiming for a significant increase in potency, solubility and selectivity, Argenta will draw on its expertise in medicinal chemistry, synthetic chemistry, computer-aided drug design and analytical chemistry.
Dr Anthony Baxter, Argenta's CEO, said: 'The Japanese pharmaceutical sector has tremendous potential and Argenta is delighted to be working with Teijin. The collaboration proves the value of having a presence in Japan.'
Relationships with Teijin have also been facilitated by Professor AGM Barrett, Professor of Chemistry at Imperial College of Science, Medicine and Technology, London, and a non-executive director of Argenta Discovery. Professor Barrett was invited to lecture to Teijin scientists at the Teijin research centre, Tokyo, during a recent lecture tour of several research groups in Japan.